Category Science and Technology
Kathy Hodgkinson and Daryl Pullman propose that high risk/high recurrence genetic diseases should come under the purview of public health.
Françoise Baylis responds to the recently announced birth of the world’s first genome edited babies and raises concerns about the scientific practice and ethical accountability.
Deborah Gleeson and Ronald Labonté object to lengthening market exclusivity for biologic medicines in the United States-Mexico-Canada Agreement.
Jason Scott Robert suggests that the creation of part-human animals in stem cell biology may generate scientific confusion.
Yeyang Su invites Impact Ethics readers to mark their calendars for the second International Summit on Human Genome Editing.
Marc-André Gagnon dispels misconceptions about the benefits of private health insurance plans and argues in favour of a universal model for pharmacare.
Landon J. Getz explores the privacy minefield of commercial DNA Sequencing, and how it has become relevant in recent news.